U.S. markets close in 3 hours 9 minutes

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
298.95+9.73 (+3.36%)
As of 12:50PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Megaphone Top

Megaphone Top

Previous Close289.22
Open292.02
Bid297.50 x 800
Ask297.56 x 800
Day's Range283.50 - 300.50
52 Week Range118.55 - 388.97
Volume192,948
Avg. Volume346,803
Market Cap28.227B
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33%
    Simply Wall St.

    BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33%

    Market forces rained on the parade of BeiGene, Ltd. ( NASDAQ:BGNE ) shareholders today, when the analysts downgraded...

  • Benzinga

    Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy

    Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B therapies. The CST study was supposed to be conducted with BeiGene Ltd (NASDAQ: BGNE), which licensed the rights to VBR in China. The company will prioritize its portfolio of next-generation core inhibitors and combinations of VBR with complementary action mechanisms and plans to advance multiple research programs and new mechanisms to human trials. By redirecting the resources previously reserved for the CST, the company sees the cash runway extended into 2023, compared to the second half of 2022, expected earlier. Assembly Bio's HBV pipeline includes three clinical-stage core inhibitor candidates and multiple research and discovery programs. Two clinical studies are underway, with one more study expected to begin during the first half of 2021. In December, the company closed its microbiome program to prioritize resources and focus on advancing its core inhibitors for chronic HBV. Assembly Bio reported disappointing results from a Phase 2 study evaluating vebicorvir in treating chronic hepatitis B virus infection patients. The study failed to achieve meaningful, sustained virologic response rates as 39 of 41 patients relapsed. Price Action: ASMB is up 1.6% at $5.62 in premarket trading on the last check Friday, while BGNE closed 1.5% lower at $329.7 on Thursday. See more from BenzingaClick here for options trades from BenzingaBeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review

    The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application seeking approval for BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström's Macroglobulinemia (WM), a type of blood cancer. The target Action date is set for October 18. In November 2019, BRUKINSA received accelerated approval in the U.S. to treat mantle cell lymphoma in adult patients who have received at least one prior therapy. In June 2020, BRUKINSA received conditional approval in China as a treatment for adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who have received at least one prior therapy and as a treatment for adult patients with mantle cell lymphoma who have received at least one prior therapy. Price Action: BGNE shares are down 0.55% at $381.83 on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaNektar Therapeutics Secures 0M From SFJ Pharma For New Study With BEMPEG/Pembrolizumab Combo In Head & Neck CancerEli Lilly's Tirzepatide Reduces A1C And Body Weight, Late-Stage Studies In Type 2 Diabetes Show© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.